Oxford Textbook of Colorectal Cancer
Published on 12. February 2026
Book
Hardback
256 pages
978-0-19-284999-1 (ISBN)
Description
Colorectal cancer is one of the most common cancers affecting both men and women worldwide. Each year, it accounts for nearly two million cases and one million deaths worldwide. The increasing incidences of morbidity and mortality present a significant global health and economic burden, particularly in low- and middle- income countries.
Over the past three decades, substantial advances have been made in screening, our understanding of colorectal carcinogenesis and the genetic basis of the disease, and refinement of surgical and oncological treatments. Advances in chemotherapy, radiotherapy, and the evolution of adjuvant and neoadjuvant treatment, biological therapies, and immunotherapy have significantly improved patient outcomes. Multidisciplinary approaches to managing metastases in the liver, lungs and peritoneum are also contributing to improved survival, even in the advanced stages of the disease.
Part of the Oxford Textbooks in Oncology series, the Oxford Textbook of Colorectal Cancer discusses these developments, including exploring emerging advances in research and clinical practice. It examines the role of artificial intelligence in diagnostics and prognosis prediction, and considers the patient as a whole, highlighting the 'third healthcare revolution' and the central contributor of all healthcare professionals involved in the patient pathway, including colorectal nurse specialists.
With contributions from internationally renowned experts, this comprehensive, multidisciplinary textbook provides an accessible, evidence-based resource for trainees and established oncologists, surgeons, specialist nurses and pharmacists, and other healthcare professionals involved in colorectal cancer care.
Over the past three decades, substantial advances have been made in screening, our understanding of colorectal carcinogenesis and the genetic basis of the disease, and refinement of surgical and oncological treatments. Advances in chemotherapy, radiotherapy, and the evolution of adjuvant and neoadjuvant treatment, biological therapies, and immunotherapy have significantly improved patient outcomes. Multidisciplinary approaches to managing metastases in the liver, lungs and peritoneum are also contributing to improved survival, even in the advanced stages of the disease.
Part of the Oxford Textbooks in Oncology series, the Oxford Textbook of Colorectal Cancer discusses these developments, including exploring emerging advances in research and clinical practice. It examines the role of artificial intelligence in diagnostics and prognosis prediction, and considers the patient as a whole, highlighting the 'third healthcare revolution' and the central contributor of all healthcare professionals involved in the patient pathway, including colorectal nurse specialists.
With contributions from internationally renowned experts, this comprehensive, multidisciplinary textbook provides an accessible, evidence-based resource for trainees and established oncologists, surgeons, specialist nurses and pharmacists, and other healthcare professionals involved in colorectal cancer care.
More details
Series
Language
English
Place of publication
Oxford
United Kingdom
Target group
Professional and scholarly
Product notice
sewn/stitched
Cloth over boards
Dimensions
Height: 278 mm
Width: 226 mm
Thickness: 23 mm
Weight
980 gr
ISBN-13
978-0-19-284999-1 (9780192849991)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
Rachel Kerr is Associate Professor of Gastrointestinal Oncology at the University of Oxford, and Consultant Medical Oncologist, and a leader of colorectal cancer trials nationally and internationally. She has spear-headed many clinical trials in the adjuvant setting of colorectal cancer and contributed significantly to this field. Through building correlative clinical outcome and tumour sample biobanks from large adjuvant trials, Rachel Kerr has helped to form our understanding of biomarkers in colorectal cancer to predict prognosis and treatment effect, as well as pioneering the roll out of toxgnostics-the germline identification of patients most at risk of toxic effects of chemotherapy.
Li Yang specializes in diagnosis and treatment of complicated diseases in the digestive system, with a focus on hepatic cirrhosis and autoimmune liver diseases. Supported by several grants from the national natural science foundation of China (NFSC) and other projects, she has published more than 1000 peer-reviewed articles in high impact journals like the Journal of Hepatology, Hepatology, Lancet Oncology, Radiology etc. Li Yang received the First Prize of the Sichuan Provincial Science and Technology Progress Award in 2019 as the first lead author, and the First Prize of China Medical Science and Technology Award in 2022 as the second lead author. She is the Deputy Editor-in-chief of national-level textbooks, such as the Digestive Internal Medicine and Digestive System and Diseases, as well as the Practical Journal of Liver Diseases, and China Medical Forum Press.
David Kerr contributes to Oxford University as Professor of Cancer Medicine and Honorary Consultant medical oncologist, where he has worked with colleagues over the past 25 years to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Oslo and Sichuan Universities and Co-Director of Oxford-Sichuan Gastrointestinal Cancer Centre.
He has an international reputation for the treatment of and research into cancer and the quality of his work has been recognised by the award of several national & international prizes, including the Tianfu Friendship Award (2022), the China Friendship Medal (2024), as well as being appointed Commander of the British Empire by Her Majesty the Queen (2002).
He has served as health adviser to three British Prime Ministers and has supported National Cancer planning in the several countries around the world.
He is currently also Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology.
Li Yang specializes in diagnosis and treatment of complicated diseases in the digestive system, with a focus on hepatic cirrhosis and autoimmune liver diseases. Supported by several grants from the national natural science foundation of China (NFSC) and other projects, she has published more than 1000 peer-reviewed articles in high impact journals like the Journal of Hepatology, Hepatology, Lancet Oncology, Radiology etc. Li Yang received the First Prize of the Sichuan Provincial Science and Technology Progress Award in 2019 as the first lead author, and the First Prize of China Medical Science and Technology Award in 2022 as the second lead author. She is the Deputy Editor-in-chief of national-level textbooks, such as the Digestive Internal Medicine and Digestive System and Diseases, as well as the Practical Journal of Liver Diseases, and China Medical Forum Press.
David Kerr contributes to Oxford University as Professor of Cancer Medicine and Honorary Consultant medical oncologist, where he has worked with colleagues over the past 25 years to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Oslo and Sichuan Universities and Co-Director of Oxford-Sichuan Gastrointestinal Cancer Centre.
He has an international reputation for the treatment of and research into cancer and the quality of his work has been recognised by the award of several national & international prizes, including the Tianfu Friendship Award (2022), the China Friendship Medal (2024), as well as being appointed Commander of the British Empire by Her Majesty the Queen (2002).
He has served as health adviser to three British Prime Ministers and has supported National Cancer planning in the several countries around the world.
He is currently also Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology.
Content
Section 1 - Pathology and aetiology 1: Anusha Amanullah and Ian Tomlinson: Colorectal cancer genetics 2: Amy Davies, Lynda McSorley, Ashley Pheely, and Eva Segelov: Lifestyle factors and the third healthcare revolution 3: Daniel Novelli and Marco Novelli: Molecular biology of sporadic colorectal cancer 4: Faiz Jabbar and David N. Church: Impact of tumour microenvironment in governing invasion, growth, and metastasis Section 2 - Screening and staging 5: Jinlin Yang, Zijing Wang, Jin Wang, Tong Liu, Yuzhi Liu, Xian Zhang, Xiuhe Lv, and Li Yang: The importance of the gut microbiome in colorectal cancer risk and treatment 6: Anoop K. Vargese and James E. East: Innovations in population screening 7: Dan Jiang, Xian Zhang, and Zijian Lu: Pathology, tumour staging, and prognostic and predictive biomarkers 8: Andreas Kleppe, Tarjei Hveem, Knut Liestol, and Havard Danielsen: Artificial intelligence and digital pathology 9: Meng Dou, Zhebin Chen, Xianhong Xu, Xiaojing Gu, Xuejiao Li, and Xin Wang: Artificial intelligence and radiomics Section 3 - Multidisciplinary management 10: Sean O> 'Cathail and Tim O> 'Brien: Controversies in the multidisciplinary management of locally advanced rectal cancer including total neoadjuvant therapy 11: Alex Gordon-Weeks, Daniel L. Hughes, and Mike A. Silva: The multidisciplinary management of colorectal liver metastases 12: Elizabeth Belcher and Michael Shackcloth: Multidisciplinary management of pulmonary metastases 13: Vasanth M. Samuel, Glen R. Guerra, and Brendan Moran: Multidisciplinary management of peritoneal metastases 14: Rebecca Muirhead and Rebecca Johnson: Integrating stereotactic ablative body radiotherapy into the multidisciplinary management of recurrent colorectal cancer 15: Ernest Hawk and Eduardo Vilar-Sanchez: Preventive agents in colorectal cancer Section 4 - Novelty interventions and personalizing the colorectal cancer pathway 16: Valentinos Kounnis and Rachel Kerr: Adjuvant treatment of colorectal cancer 17: Josep Tabernero, Elena Elez, Javier Ros, and Nadia Saoudi-Gonzalez: The precision medicine approach for advanced and metastatic colorectal cancer 18: Sarah Chamberlain and Rachel Kerr: The expanding landscape of immunotherapy in colorectal cancer 19: Jesus Garcia-Foncillas: Novel targets for drug development 20: Vanessa Shearwood and Alexandra Poole: Support for the colorectal cancer patient before, during, and after treatment